Cargando…

Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis

BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleos...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhu-Qing, Han, Ying-Chao, Zhang, Xi, Chu, Li, Fang, Jue-Min, Zhao, Hua-Xin, Chen, Yi-Jing, Xu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903621/
https://www.ncbi.nlm.nih.gov/pubmed/24475233
http://dx.doi.org/10.1371/journal.pone.0087103
_version_ 1782301124023287808
author Liu, Zhu-Qing
Han, Ying-Chao
Zhang, Xi
Chu, Li
Fang, Jue-Min
Zhao, Hua-Xin
Chen, Yi-Jing
Xu, Qing
author_facet Liu, Zhu-Qing
Han, Ying-Chao
Zhang, Xi
Chu, Li
Fang, Jue-Min
Zhao, Hua-Xin
Chen, Yi-Jing
Xu, Qing
author_sort Liu, Zhu-Qing
collection PubMed
description BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37–3.64) and 2.67 (95% CI, 1.87–3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76–4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy.
format Online
Article
Text
id pubmed-3903621
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39036212014-01-28 Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis Liu, Zhu-Qing Han, Ying-Chao Zhang, Xi Chu, Li Fang, Jue-Min Zhao, Hua-Xin Chen, Yi-Jing Xu, Qing PLoS One Research Article BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37–3.64) and 2.67 (95% CI, 1.87–3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76–4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy. Public Library of Science 2014-01-27 /pmc/articles/PMC3903621/ /pubmed/24475233 http://dx.doi.org/10.1371/journal.pone.0087103 Text en © 2014 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Liu, Zhu-Qing
Han, Ying-Chao
Zhang, Xi
Chu, Li
Fang, Jue-Min
Zhao, Hua-Xin
Chen, Yi-Jing
Xu, Qing
Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title_full Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title_fullStr Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title_full_unstemmed Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title_short Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
title_sort prognostic value of human equilibrative nucleosidetransporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903621/
https://www.ncbi.nlm.nih.gov/pubmed/24475233
http://dx.doi.org/10.1371/journal.pone.0087103
work_keys_str_mv AT liuzhuqing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT hanyingchao prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT zhangxi prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT chuli prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT fangjuemin prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT zhaohuaxin prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT chenyijing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis
AT xuqing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis